Clinique Jules Verne

The trials here

What the 22 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis12 trials
• Crohn's disease8 trials
• Colorectal cancer2 trials
• Macular degeneration1 trial
• Obesity1 trial

Phase

• Phase 27 trials
• Phase 36 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Recruiting8 trials
• Completed6 trials
• Active, not recruiting4 trials
• Not yet recruiting4 trials

Lead sponsor

• AbbVie3 trials
• Janssen Research & Development, LLC2 trials
• Nantes University Hospital2 trials
• Spyre Therapeutics, Inc.2 trials
• University Hospital, Bordeaux2 trials
• and 11 more

Running trials

• Not yet recruiting

  Follow-up After Oncological Resection by Endoscopic Colorectal ESD (Endoscopic Submucosal Dissection)

  NCT07871227· University Hospital, Bordeaux· Source

  Contact: Bertrand BRIEAU, MD

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.

  NCT07299071· University Hospital, Bordeaux· Source

  Contact: Bertrand BRIEAU, MD

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT07064759· Phase 3· 4D Molecular Therapeutics· Source

  Contact: 4DMT Patient Advocacy

• Recruiting

  Evaluation of the Acceptability and Therapeutic Maintenance After Substitution of Ustekinumab With a Biosimilar

  NCT07077681· EG Labo· Source

  Contact: Marie FREYSSINET, MD

• Recruiting

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  Inflammatory Bowel Disease Cohort in Nantes

  NCT06256393· Nantes University Hospital· Source

  Contact: Mathurin FLAMANT, MD

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

  NCT06180382· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· AbbVie· Source

• Recruiting

  Evaluation of Omentopexy on Gastro-oesophageal Reflux Following Sleeve Gastrectomy

  NCT04994665· Centre Hospitalier Departemental Vendee· Source

  Contact: Laurent POTIRON (principal investigator)

• Active, not recruiting

  Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

  NCT04524611· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

  NCT03398135· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease5 recruiting
• Ulcerative colitis5 recruiting
• Colorectal cancer2 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

  NCT05588843· Phase 2· Sanofi· Source

• Completed

  A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

  NCT05499130· Phase 2· Teva Branded Pharmaceutical Products R&D, Inc.· Source

• Completed

  Simplified Bowel Preparation Versus Standard Bowel Preparation Before Capsule Endoscopy in Patients With Crohn's Disease

  NCT05117996· Nantes University Hospital· Source

• Completed

  Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT04424303· Pfizer· Source